859 related articles for article (PubMed ID: 22641678)
1. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
2. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
Liu L; Sun M; Wang Z
Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
[TBL] [Abstract][Full Text] [Related]
3. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
[TBL] [Abstract][Full Text] [Related]
6. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.
Wang W; Ma Y; Li J; Shi HS; Wang LQ; Guo FC; Zhang J; Li D; Mo BH; Wen F; Liu T; Liu YT; Wang YS; Wei YQ
Gene Ther; 2013 Oct; 20(10):970-8. PubMed ID: 23636245
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
Gross G; Eshhar Z
Annu Rev Pharmacol Toxicol; 2016; 56():59-83. PubMed ID: 26738472
[TBL] [Abstract][Full Text] [Related]
8. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
9. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
10. Establishing guidelines for CAR-T cells: challenges and considerations.
Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
[TBL] [Abstract][Full Text] [Related]
11. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
Chmielewski M; Kopecky C; Hombach AA; Abken H
Cancer Res; 2011 Sep; 71(17):5697-706. PubMed ID: 21742772
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
13. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
17. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
Atanackovic D; Radhakrishnan SV; Bhardwaj N; Luetkens T
Br J Haematol; 2016 Mar; 172(5):685-98. PubMed ID: 26791002
[TBL] [Abstract][Full Text] [Related]
19. Preclinical development of T cell receptor gene therapy.
Bendle GM; Haanen JB; Schumacher TN
Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
[TBL] [Abstract][Full Text] [Related]
20. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
